Zydus USFDA inspection ends with one observation

Zydus Lifesciences said its USFDA cGMP inspection at its Ahmedabad SEZ II facility (Sept 21–28) concluded with one observation and no data integrity issues. Days earlier, its New Jersey pharmacovigilance inspection ended with nil observations. The company's Q1 profit fell 35.9% YoY to ₹939.8 crore, while revenue rose 22% to ₹8,017 crore.